Insights
Search Results
Client Highlights
6.05.26
Wilson Sonsini Advises SewerAI on Strategic Investment
On June 2, 2026, SewerAI, a leading AI platform for sewer and underground infrastructure intelligence, announced a major strategic investment led by JMI Equity, a leading growth equity software investor based in the greater Washington, D.C., area and San Diego, with continued participation from Innovius Capital, Epic Ventures, and Bentley Systems. Wilson Sonsini Goodrich & Rosati advised SewerAI on the transaction.
Client Highlights
3.30.26
Wilson Sonsini Advises Octopus Energy on Majority Stake Acquisition of Uplight
On March 24, 2026, Octopus Energy Group, a global clean energy and technology business driving the affordable, green energy system of the future, will cement its expansion in the U.S. by acquiring a majority stake in Uplight, a leading provider of customer engagement and flexibility management solutions that rapidly transform customer participation into dependable grid capacity. The deal is made in partnership with Schneider Electric, a global energy technology leader trusted by utilities worldwide, which will remain as a significant minority partner. The transaction is subject to customary regulatory approvals and is expected to complete later this year. Wilson Sonsini Goodrich & Rosati advised Octopus Energy on the transaction.
Client Highlights
2.19.26
Wilson Sonsini Advises Griptape on Acquisition by Foundry
On February 18, 2026, Foundry, a leading developer of creative software for the media and entertainment industry, announced the completion of its acquisition of Griptape, a pioneer in enterprise-grade AI orchestration. Wilson Sonsini Goodrich & Rosati advised Griptape on the transaction.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
As described by Foundry, the acquisition accelerates Foundry's AI strategy, adding critical orchestration capabilities to complement the AI-powered features in Foundry's product portfolio. It represents the next evolution of this strategy, enabling studios to orchestrate multiple AI models and agents within secure, professional workflows that connect seamlessly with Foundry's existing creative toolsets. As studios shift from experimentation to everyday production use, the need for better control of AI models has become critical. Griptape enables controlled access to rapidly evolving open-source and commercial AI models in a user-friendly framework, while balancing the strict security and traceability required by major production environments.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes: